Intranasal vaccine – iNCOVACC is available for use in the private sector under Covid-19 vaccination programme, according to the Ministry of Health & Family Welfare (MoHFW). The technical details of iNCOVACC are as follows:
Vaccine name: iNCOVACC; Manufacturer Name: Bharat Biotech (BBIL); Vaccine type: Intranasal; Vaccine description (Type): Covid-19 Vaccine, Intranasal Recombinant (Adenovirus Vector based); Dose per vial: Two doses; Eligible Beneficiaries 18 years and above: 18 Yrs and above for Primary Vaccination and third dose (Precaution Dose); Heterologous precaution dose for people of 18 years and above, after 6 months of primary vaccination (two doses) of Covaxin or Covishield.
Doses per beneficiary: 0.5ml per dose in 8 drops, (4 drops in each nostril); No. of Doses: Two doses for primary schedule
Dose Frequency: 28 days apart (Primary schedule)
According to MoHFW, the necessary changes on Co-WIN platform for same are being made.
We are sorry that this post was not useful for you!
Let us improve this post!
Tell us how we can improve this post?